PDUFA Workload Sets Records, But Inflation Generates More Revenue

The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.

White round tablets lie in front of President Franklin, who is depicted on a hundred-dollar bill. The concept of the high cost of medicine, pharmaceuticals. - Image
The workload and inflation adjustment formulas affect the PDUFA revenue target, which is used to set individual user fees. • Source: Shutterstock

Despite another year with record workload levels, the US Food and Drug Administration's prescription drug user fee program revenue was actually more affected by inflation.

For the first time in seven years, the FDA's inflation formula added more money to the prescription drug user fee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Review Pathways

More from Pathways & Standards

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By 

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

US FDA Asking Questions About Commissioner’s Voucher Program With Details Scarce

 

FDA staff are trying to plan for program implementation in the absence of critical eligibility and other details, although guidance may be coming soon.